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A B S T R A C T
Background
The relevance to coronary heart disease (CHD) of cytokines that govern inflammatory
cascades, such as interleukin-6 (IL-6), may be underestimated because such mediators are short
acting and prone to fluctuations. We evaluated associations of long-term circulating IL-6 levels
with CHD risk (defined as nonfatal myocardial infarction [MI] or fatal CHD) in two population-
based cohorts, involving serial measurements to enable correction for within-person variability.
We updated a systematic review to put the new findings in context.
Methods and Findings
Measurements were made in samples obtained at baseline from 2,138 patients who had a
first-ever nonfatal MI or died of CHD during follow-up, and from 4,267 controls in two cohorts
comprising 24,230 participants. Correction for within-person variability was made using data
from repeat measurements taken several years apart in several hundred participants. The year-
to-year variability of IL-6 values within individuals was relatively high (regression dilution ratios
of 0.41, 95% confidence interval [CI] 0.28–0.53, over 4 y, and 0.35, 95% CI 0.23–0.48, over 12 y).
Ignoring this variability, we found an odds ratio for CHD, adjusted for several established risk
factors, of 1.46 (95% CI 1.29–1.65) per 2 standard deviation (SD) increase of baseline IL-6 values,
similar to that for baseline C-reactive protein. After correction for within-person variability, the
odds ratio for CHD was 2.14 (95% CI 1.45–3.15) with long-term average (‘‘usual’’) IL-6, similar to
those for some established risk factors. Increasing IL-6 levels were associated with progressively
increasing CHD risk. An updated systematic review of electronic databases and other sources
identified 15 relevant previous population-based prospective studies of IL-6 and clinical
coronary outcomes (i.e., MI or coronary death). Including the two current studies, the 17
available prospective studies gave a combined odds ratio of 1.61 (95% CI 1.42–1.83) per 2 SD
increase in baseline IL-6 (corresponding to an odds ratio of 3.34 [95% CI 2.45–4.56] per 2 SD
increase in usual [long-term average] IL-6 levels).
Conclusions
Long-term IL-6 levels are associated with CHD risk about as strongly as are some major
established risk factors, but causality remains uncertain. These findings highlight the potential
relevance of IL-6–mediated pathways to CHD.
The Editors’ Summary of this article follows the references.
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Introduction
As atherosclerosis may be an inflammatory condition [1],
there is interest in the relevance of various circulating
inflammatory markers to cardiovascular diseases [2]. Inflam-
matory cascades are propagated by proximal mediators such as
interleukin-6 (IL-6), a cytokine produced in various tissues. IL-
6 exerts proinflammatory effects including stimulation of the
liver to produce positive acute-phase proteins during tissue
injury or infection [3–5]. Previous epidemiological studies of
coronary heart disease (CHD) and inflammation have focused
mainly on ‘‘downstream’’ acute phase reactants (e.g., fibrinogen
[6] and C-reactive protein [7]) because they are comparatively
stable within individuals over time. By contrast, investigation
of IL-6 in CHD has been relatively limited because of its
shorter half-life (,2 h) and greater within-person variability.
Published prospective studies of IL-6 have yielded divergent
odds ratios ranging from 1.0 to 3.0 [8–21]. However, as each
report has typically comprised only a few hundred patients
with CHD, the estimates involve wide, overlapping confidence
intervals (CIs). A recent nonquantitative review [22] reported
on published data from five prospective studies of IL-6 and
CHD, but it comprised only about one-third of the currently
published evidence, and it mixed results of studies involving
different vascular outcomes and of different study designs.
Even a more comprehensive and consistent review of
published reports would not, however, have been able to
assess appropriately IL-6–CHD associations, because no
individual prospective study to our knowledge has yet made
allowances for the cytokine’s within-person variability. Owing
to fluctuations in IL-6 values over time, comparisons using only
baseline values may yield biased estimates of the true
association, which can be corrected, for the most part, by
using data from paired measurements [23–27] (see Methods).
We report new data on IL-6 levels from two population-
based prospective cohorts, the Reykjavik Study and the
British Regional Heart Study (BRHS), which together
comprise 24,230 predominantly middle-aged individuals with
an average of almost 20 years of follow-up per participant.
After exclusion of participants with any evidence of baseline
coronary disease or stroke, 2,138 incident cases of CHD were
available for the present analyses, more than four times as
many CHD cases as in the largest previous study [13]. Paired
measurements were made in random samples of participants
in both studies in order to quantify (and correct for) long-
term variation in IL-6 levels. We contextualised our new data
by conducting an updated systematic review of all prospective
studies of IL-6 and CHD based only in essentially general
populations, comprising a further 3,592 CHD cases (defined
as myocardial infarction [MI] or death attributed to CHD by
World Health Organization [WHO] or similar criteria).
Furthermore, we used new data from serial measurements
made in our two prospective studies to correct for within-
person variability in the studies included in the meta-analysis.
The focus of the current report is on the magnitude of the
association of IL-6 levels with CHD (rather than on the
separate issue of risk prediction).
Methods
Study Population
The Reykjavik Study and the BRHS were initiated in 1967
and 1978, respectively, and have each been described in detail
previously [28,29]. In the Reykjavik Study, men and women
born between 1907 and 1935, resident in Reykjavik, Iceland,
and its adjacent communities on December 1, 1966, were
identified in the national population register and were invited
to participate in the study during five stages of recruitment
between 1967 and 1991. A total of 8,888 male and 9,681 female
participants aged 33–86 y without a history of MI were
recruited (72% response rate). Nurses administered ques-
tionnaires, made physical measurements, recorded an electro-
cardiogram (ECG), performed spirometry, and collected
fasting venous blood samples to prepare serum that was
stored at 20 8C for subsequent analysis. History of diabetes
was self-reported. All participants have been monitored
subsequently for cause-specific mortality (ascertained from
central registers on the basis of a death certificate; ICD-9
codes 410–414 were used for CHD death) and for cardiovas-
cular morbidity (diagnosis of MI was based on MONICA
criteria), with a loss to follow-up of only about 0.6% to date.
The BRHS enrolled 7,735 men aged 40–59 y (response rate
78%) randomly selected from general practice registers in
each of 24 British towns during 1978–1980. Nurses adminis-
tered questionnaires, made physical measurements, recorded
an ECG, performed spirometry, and collected nonfasting
venous blood samples from 5,661 men in 18 of the towns.
Serum was obtained from the baseline blood samples and
stored at 20 8C for subsequent analysis. Participants were
monitored for all-cause mortality (ascertained through the
National Health Service central registers, using ICD-9 codes
410–414 for CHD) and for cardiovascular morbidity (using
general practitioners’ reports and records, with diagnosis of
MI based on WHO criteria), with a loss to follow-up of less
than 1% to date. History of diabetes was, again, self-reported.
Relevant institutional review boards approved each study, and
participants provided informed consent.
Laboratory Measurements
IL-6 measurements were made in the Reykjavik Study and
BRHS on available serum samples, using a sensitive enzyme-
linked immunosorbent assay (ELISA; R & D Systems) in the
Glasgow laboratory by the same technicians blinded to
participants’ disease status. The intra-assay coefficient of
variability was 7%, and the inter-assay coefficient of
variability was 8%. Measurements were made in pairs of
samples from a randomly selected subset of baseline
participants in each study, comprising 258 participants in
the BRHS (samples collected at a median interval of about 4 y
apart) and 300 participants in the Reykjavik Study (samples
collected at a median interval of about 12 y apart). Because
the temperature of storage of the initial BRHS samples was
20 8C, whereas it was70 8C at the resurvey, there was scope
in this study for slight overestimation of within-person
variability in IL-6 levels, encouraging comparison of its
findings with those from the Reykjavik Study in which
conditions at the two surveys were identical. Lipid and other
biochemical measurements involved standard assays, as
previously described [28–30].
Statistical Analyses
In both the Reykjavik Study and BRHS, two or three
control participants were randomly selected and frequency
matched to incident CHD cases in 5-y age bands (and, in the
Reykjavik Study, on calendar year of recruitment and sex; and
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in the all-male BRHS by town of residence), thereby obtaining
the same joint frequency distributions of these factors among
controls and cases. To limit any biases due to preexisting
disease, prespecified principal analyses were restricted to the
2,138 individuals with CHD and 4,267 control participants
who did not have baseline evidence of CHD or stroke (i.e.,
without baseline ECG abnormalities or self-reported preva-
lent MI, stroke, or angina) in a nested case–control
comparison. Subsidiary analyses excluded patients who had
CHD outcomes in the first 5 y of follow-up. Odds ratios for
CHD per 2 standard deviations (SDs) increase in the natural
logarithm (loge) of IL-6 were calculated using unconditional
logistic regression (Stata, version 9). The odds ratios for a 2
SD change is similar to a comparison of extreme thirds of IL-
6 values in a population. Analyses to investigate the shape of
the IL-6–CHD association were conducted for groups defined
by fifths of baseline IL-6 values in controls, with correspond-
ing 95% CIs estimated from floating variances that reflect the
amount of information underlying each group (including the
reference group) [31–33]. To avoid overadjustment, adjust-
ment for other inflammatory markers (e.g., C-reactive
protein) was reserved for subsidiary analyses.
Correction for Regression Dilution
Data from paired measurements in the Reykjavik Study,
which coincided with approximately the midpoint of this
study’s follow-up duration, were used to quantify and to
correct for within-person variability in IL-6 and other risk
factors, which are likely to be measured with error owing to
both within-person biological variability and laboratory
variability. Adjusted regression dilution ratios were calcu-
lated by Rosner’s regression method [26] to quantify the
extent to which single measurements of the markers reflect
their long term average (i.e., ‘‘usual’’) levels. Paired measure-
ments from the BRHS were used solely for comparison.
Statistical significance of the difference in the strength of
CHD association with IL-6 compared to other markers was
determined from differences in the loge odds ratios per 2 SD
increase in 2,000 bootstrap samples of the data [34].
Uncertainties in the regression dilution ratios calculated
from the 300 participants with repeats in the Reykjavik Study
were incorporated into the CIs for CHD associations by
adding to the observed regression dilution ratios an error
term sampled from the regression dilution ratio distribution
on each bootstrap sample. This correction was applied to
odds ratios both in the Reykjavik Study and in the BRHS.
Correction for multivariate within-person variability in both
IL-6 and error-prone confounders was achieved using a
multivariable linear regression model [27] from which
conditional expectations of usual levels of IL-6 and the
error-prone confounders were predicted and then substi-
tuted in place of the baseline levels in the logistic model to
obtain the corrected odds ratios. Odds ratios for loge C-
reactive protein, loge erythrocyte sedimentation rate, von
Willebrand factor, systolic blood pressure, and total choles-
terol were calculated using methods described for loge IL-6.
Systematic Review
A systematic review of prospective, population-based
studies of circulating IL-6 levels and CHD risk was conducted
according to QUOROM (Quality of Reporting of Meta-
analyses) guidelines (Texts S1 and S2). Studies published
before May 2007 were sought using computer-based databases
(MEDLINE, EMBASE, and Science Citation Index), and by
scanning the reference lists of articles identified for all
relevant studies and review articles (including meta-analyses).
The computer-based searches combined free and MeSH
search terms and combinations of key words related to IL-6
(e.g., ‘‘interleukin-6’’, ‘‘IL-6’’) and coronary disease (e.g.,
‘‘coronary heart disease’’, ‘‘myocardial ischemia’’, ‘‘myocardial
infarction’’, ‘‘CHD’’, ‘‘heart attack’’, ‘‘MI’’) without restricting
language or publication date (flow chart in Figure 1). Data
were extracted, where available, on study, geographic loca-
tion, publication date, sample population, sampling methods
(i.e., complete, random, etc.), sample source (plasma/serum),
nature of sample (i.e., fresh or frozen, storage temperature),
fasting status at time of blood sampling (duration of any
fasting), blinding of lab worker to case versus control status,
assay type, source and standard, analysis methods and units,
case definition, any matching criteria, sample size (of total
cohort and numbers with IL-6 measurements), numbers of
cases (total, fatal CHD, nonfatal MI), numbers of controls,
mean age, sex, time of baseline survey, duration of follow-up,
mean or median IL-6 values, adjustment of confounders, and
summary statistics. These details were extracted independ-
ently by two investigators using a prespecified data extraction
form (Table S1). Discrepancies were resolved by discussion
and by adjudication of a third reviewer.
Prospective (cohort or ‘‘nested’’ case–control) studies based
in essentially general populations (i.e., where participants
were not selected on the basis of preexisting disease) with
samples taken at baseline (i.e., prior to the occurrence of
events) were eligible for inclusion in the current review.
Analyses were restricted to studies with at least 1 y of follow-
up and with outcomes defined as MI or coronary death. Three
studies of IL-6 (comprising approximately 450 CHD cases or
Figure 1. QUOROM Flow Diagram Summarising the Search Strategy for
Meta-analysis of IL-6 and CHD Outcomes in Generally Healthy
Populations
doi:10.1371/journal.pmed.0050078.g001
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7% of the total) [35–37] were excluded because they reported
on composite cardiovascular outcomes rather than for MI or
fatal CHD separately. To limit potential biases, analyses
involved only within-study comparisons (i.e., cases and
controls were directly compared only within each cohort).
Results of the studies were combined using a random effects
model. Associations of usual levels of IL-6 and CHD were
estimated using correction factors derived from the Reykjavik
Study and BRHS. Odds and hazard ratios were assumed to
approximate the same measure of relative risk. Heterogeneity
was quantified by the I2 statistic [38,39], and subsidiary
subgroup analyses were conducted using metaregression [40]
to investigate several study-level characteristics potentially
explaining heterogeneity, including population sampling
methods, duration of follow-up, source and type of IL-6
assay, blood storage temperature, geographical region,
number of CHD cases, sex, degree of adjustment of other
cardiovascular risk factors, and whether individuals with
CHD at baseline were excluded from analysis. Test statistics
from the metaregression based on the F-distribution were
used to assess the statistical significance of these study-level
characteristics in explaining heterogeneity.
Results
Baseline Correlates of IL-6 Levels
In the Reykjavik study, the median duration of follow-up of
participants with CHD and control participants were 14 y and
Table 1. Baseline Characteristics of Incident CHD Cases and Controls without Known Evidence of Coronary Disease at Baseline Nested
within the Reykjavik Study and BRHS
Type of Marker Variables Reykjavik Study BRHS
Cases Controls p-Value Cases Controls p-Value
n Mean 6 SD
or n (%)
n Mean 6 SD
or n (%)
n Mean 6 SD
or n (%)
n Mean 6 SD
or n (%)
Questionnaire Age (years) 1,768 53.9 6 8.6 3,303 54.9 6 8.9 Matched 370 52.1 6 5.3 964 52.3 6 5.4 Matched
Male sex 1,768 1,259 (71%) 3,303 2,281 (69%) Matched 370 370 (100%) 964 964 (100%) All male
Current cigarette/
pipe/cigar smoker
1,768 1,068 (60%) 3,303 1,618 (49%) ,0.0001 369 197 (53%) 963 399 (41%) ,0.0001
Current cigarette smoker 1,767 728 (41%) 3,299 1,055 (32%) ,0.0001 369 197 (53%) 963 399 (41%) ,0.0001
Self-reported
history of diabetes
1,768 42 (2%) 3,303 46 (1%) 0.011 370 9 (2%) 964 13 (1%) 0.164
Physical
measurements
Height (m) 1,766 1.71 6 0.09 3,289 1.72 6 0.09 0.181 370 1.72 6 0.06 964 1.73 6 0.07 0.048
Weight (kg) 1,762 76.5 6 13.9 3,290 75 6 13.5 ,0.0001 370 75.9 6 10.7 964 76.1 6 11.3 0.765
Body mass index (kg/m2) 1,762 26 6 3.9 3,282 25.4 6 3.8 ,0.0001 370 25.5 6 3.1 964 25.4 6 3.3 0.408
Systolic blood
pressure (mm Hg)
1,767 146 6 24 3,290 142 6 22 ,0.0001 368 152 6 21 964 146 6 21 ,0.0001
Diastolic blood
pressure (mm Hg)
1,765 91 6 12 3,288 88 6 12 ,0.0001 368 85 6 13 964 83 6 13 0.001
Forced expiratory volume (l/s) 1,744 2.84 6 0.87 3,226 2.87 6 0.86 0.305 365 3.18 6 0.7 950 3.28 6 0.76 0.033
Lipids and
metabolic factors
Total cholesterol
(mmol/l)
1,767 6.88 6 1.19 3,297 6.40 6 1.12 ,0.0001 369 6.60 6 1.02 961 6.16 6 0.99 ,0.0001
High-density lipoprotein
cholesterol (mmol/l)a
— — — — — 365 1.10 6 0.26 945 1.15 6 0.26 0.001
Loge triglycerides
(loge mmol/l)
1,674 0.155 6 0.451 3,087 0.025 6 0.439 ,0.0001 365 0.645 6 0.523 954 0.511 6 0.532 ,0.0001
Loge lipoprotein(a)
(loge mg/l)
1,764 1.24 6 1.61 3,302 1.59 6 1.73 ,0.0001 368 1.09 6 1.17 961 0.97 6 1.06 0.080
Fasting glucose (mmol/l) 1,756 4.6 6 1.05 3,278 4.53 6 0.76 0.004 369 5.77 6 1.69 961 5.61 6 1.29 0.073
Inflammatory
markers
Log insulin (loge mU/l)
a — — — — — 369 4.5 6 0.8 962 4.4 6 0.8 0.013
Loge IL-6 (loge pg/ml) 1,768 0.78 6 0.74 3,303 0.65 6 0.76 ,0.0001 370 0.97 6 0.62 964 0.79 6 0.63 ,0.0001
Loge C-reactive
protein (loge mg/l)
1,751 0.49 6 1.09 3,281 0.22 6 1.11 ,0.0001 290 0.8 6 1.15 773 0.3 6 1.2 ,0.0001
Loge serum amyloid A
protein (loge mg/l)
a
— — — — — 290 2.08 6 0.73 773 1.92 6 0.68 0.001
Loge erythrocyte
sedimentation
rate (loge mm/h)
b
1,692 1.98 6 0.97 3,130 1.84 6 0.96 ,0.0001 — — — — —
Leukocyte count (3109/l)a — — — — — 357 7.7 6 1.8 926 7.2 6 1.8 ,0.0001
von Willebrand factor (IU/dl) 1,758 115 6 46 3,283 113 6 45 0.046 370 115 6 42 964 111 6 43 0.153
Other markers Serum creatinine (lmol/l) 1,751 88.9 6 23.5 3,268 87.8 6 47.4 0.329 369 98.1 6 13.4 961 99.1 6 18.6 0.323
Uric acid (lmol/l) 1,766 310 6 71 3,297 299 6 70 ,0.0001 368 357 6 66 960 350 6 68 0.098
Hemoglobin (mmol/l)b 1,752 149 6 13 3,279 146 6 13 ,0.0001 — — — — —
Hematocrit (%) 1,752 44.9 6 3.5 3,280 44.3 6 3.5 ,0.0001 357 44.8 6 3.1 926 44 6 3.2 ,0.0001
aAvailable only in BRHS.
bAvailable only in Reykjavik Study.
doi:10.1371/journal.pmed.0050078.t001
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23 y, respectively; in the BRHS, the corresponding durations
were 9 y and 17 y, respectively. IL-6 levels were significantly
higher in those with CHD than in control individuals in both
the Reykjavik Study and in the BRHS, as were levels of several
established cardiovascular risk factors (Table 1). Mean IL-6
levels were slightly higher in the male-only BRHS compared
with the mixed-sex Reykjavik study. As shown in Table S2,
baseline IL-6 levels were positively and highly significantly (p
, 0.0001) associated with age, smoking, systolic blood
pressure, and concentrations of triglycerides, fasting glucose,
and several inflammatory markers (including C-reactive
protein and the erythrocyte sedimentation rate), and some-
what less strongly with body mass index (p, 0.001). IL-6 levels
were inversely associated with total cholesterol concentrations
(p , 0.01). With the exception of correlations of IL-6 with
smoking and measured inflammatory markers (for which the
Pearson coefficient generally ranged between 0.20 and 0.43),
even the highly significant correlations of IL-6 with other
characteristics tended to be relatively small in magnitude.
Baseline IL-6 Levels and Incident CHD
Table 2 provides odds ratios for CHD per 2 SD increase in
baseline loge IL-6 levels. The minimally adjusted odds ratios
(95% CI) for CHD per 2 SD increase were 1.48 (1.31–1.68) in
the Reykjavik Study, 2.12 (1.58–2.84) in the BRHS, and 1.57
(1.40–1.76) in the combined dataset. After further adjustment
for smoking status and several other established cardiovas-
cular risk factors, the odds ratio per 2 SD increase fell to 1.38
(1.21–1.57) in the Reykjavik Study, 2.08 (1.51–2.87) in the
BRHS, and 1.46 (1.29–1.65) in the combined dataset. Odds
ratios did not change materially after exclusion of CHD
outcomes recorded during the first 5 y of follow-up (odds
ratio [95% CI] per 2 SD increase: 1.41 [1.24–1.60]) or in
analyses including individuals with prevalent CHD at baseline
(1.55 [1.38–1.73]). CHD risk increased continuously with
increasing fifths of circulating IL-6 concentrations (Figure
2). Odds ratios did not vary substantially by levels of severalTa
b
le
2
.
R
e
la
ti
ve
O
d
d
s
o
f
C
H
D
p
e
r
2
SD
In
cr
e
as
e
in
B
as
e
lin
e
Lo
g
e
IL
-6
Le
ve
ls
in
P
ar
ti
ci
p
an
ts
w
it
h
o
u
t
K
n
o
w
n
C
o
ro
n
ar
y
D
is
e
as
e
at
B
as
e
lin
e
in
th
e
R
e
yk
ja
vi
k
St
u
d
y
an
d
th
e
B
R
H
S
S
tu
d
y
N
u
m
b
e
r
o
f
C
a
se
s
(n
)
N
u
m
b
e
r
o
f
C
o
n
tr
o
ls
(n
)
A
d
ju
st
e
d
fo
r
A
g
e
,
S
e
x
,
P
e
ri
o
d
,
a
n
d
T
o
w
n
A
d
ju
st
e
d
fo
r
A
g
e
,
S
e
x
,
P
e
ri
o
d
,
T
o
w
n
,
a
n
d
S
m
o
k
in
g
S
ta
tu
s
A
d
ju
st
e
d
fo
r
A
g
e
,
S
e
x
,
P
e
ri
o
d
,
T
o
w
n
,
S
m
o
k
in
g
S
ta
tu
s,
a
n
d
O
th
e
r
E
st
a
b
li
sh
e
d
C
H
D
R
is
k
F
a
ct
o
rs
a
A
d
ju
st
e
d
fo
r
A
g
e
,
S
e
x
,
P
e
ri
o
d
,
T
o
w
n
,
S
m
o
k
in
g
S
ta
tu
s,
O
th
e
r
E
st
a
b
li
sh
e
d
C
H
D
R
is
k
F
a
ct
o
rs
,
a
n
d
C
R
P
b
O
d
d
s
R
a
ti
o
(9
5
%
C
I)
v2
O
d
d
s
R
a
ti
o
(9
5
%
C
I)
v2
O
d
d
s
R
a
ti
o
(9
5
%
C
I)
v2
O
d
d
s
R
a
ti
o
(9
5
%
C
I)
v2
R
e
yk
ja
vi
k
St
u
d
y
1
,7
6
8
3
,3
0
3
1
.4
8
(1
.3
1
–
1
.6
8
)
—
1
.3
8
(1
.2
2
–
1
.5
7
)
—
1
.3
8
(1
.2
1
–
1
.5
7
)
—
1
.2
4
(1
.0
7
–
1
.4
2
)
—
B
R
H
S
3
7
0
9
6
4
2
.1
2
(1
.5
8
–
2
.8
4
)
—
1
.9
4
(1
.4
3
–
2
.6
3
)
—
2
.0
8
(1
.5
1
–
2
.8
7
)
—
1
.5
1
(1
.0
0
–
2
.2
7
)
—
C
o
m
b
in
e
d
2
,1
3
8
4
,2
6
7
1
.5
7
(1
.4
0
–
1
.7
6
)
5
9
1
.4
5
(1
.2
9
–
1
.6
3
)
4
0
1
.4
6
(1
.2
9
–
1
.6
5
)
3
8
1
.2
6
(1
.1
0
–
1
.4
4
)
1
1
C
o
m
p
ar
is
o
n
s
ar
e
re
p
o
rt
e
d
p
e
r
2
SD
in
cr
e
as
e
.T
h
e
SD
fo
r
b
as
e
lin
e
lo
g
e
IL
-6
va
lu
e
s
in
th
e
tw
o
st
u
d
ie
s
co
m
b
in
e
d
w
as
0
.7
4
lo
g
p
g
/m
l,
th
e
re
fo
re
2
SD
in
cr
e
as
e
in
lo
g
e
IL
-6
co
rr
e
sp
o
n
d
s
to
ap
p
ro
xi
m
at
e
q
u
ad
ru
p
lin
g
o
f
IL
-6
le
ve
ls
si
n
ce
e
23
0
.7
4
¼
4
.4
.W
al
d
v2
st
at
is
ti
cs
o
f
w
h
e
th
e
r
IL
-6
is
si
g
n
if
ic
an
tl
y
as
so
ci
at
e
d
w
it
h
C
H
D
ar
e
p
re
se
n
te
d
fo
r
th
e
co
m
b
in
e
d
an
al
ys
e
s.
aT
h
e
ad
ju
st
e
d
o
d
d
s
ra
ti
o
s
fo
r
C
H
D
in
th
e
co
m
b
in
e
d
an
al
ys
is
w
e
re
1
.9
4
(1
.6
0
,
2
.3
4
)
fo
r
th
e
to
p
fi
ft
h
ve
rs
u
s
th
e
b
o
tt
o
m
fi
ft
h
,
an
d
1
.7
2
(1
.4
6
,
2
.0
4
)
fo
r
th
e
to
p
q
u
ar
te
r
ve
rs
u
s
th
e
b
o
tt
o
m
q
u
ar
te
r
o
f
IL
-6
le
ve
ls
.
b
B
e
ca
u
se
o
f
m
is
si
n
g
va
lu
e
s,
th
e
m
o
d
e
l
w
it
h
fu
rt
h
e
r
ad
ju
st
m
en
t
fo
r
C
-r
e
ac
ti
ve
p
ro
te
in
(C
R
P
)
le
ve
ls
in
vo
lv
ed
1
,9
3
5
C
H
D
ca
se
s
an
d
3
,7
9
8
co
n
tr
o
ls
.
In
d
iv
id
u
al
s
w
it
h
e
vi
d
e
n
ce
o
f
e
le
ct
ro
ca
rd
io
g
ra
m
ab
n
o
rm
al
it
ie
s,
p
re
vi
o
u
s
M
I,
o
r
h
is
to
ry
o
f
an
g
in
a
at
th
e
b
as
e
lin
e
su
rv
e
y
w
e
re
e
xc
lu
d
e
d
fr
o
m
th
e
se
an
al
ys
e
s.
P
e
ri
o
d
re
fe
rs
to
5
-y
ca
le
n
d
ar
p
e
ri
o
d
s
o
f
re
cr
u
it
m
e
n
t;
to
w
n
re
fe
rs
to
to
w
n
o
f
re
cr
u
it
m
e
n
t;
e
st
ab
lis
h
e
d
C
H
D
ri
sk
fa
ct
o
rs
in
cl
u
d
ed
sy
st
o
lic
b
lo
o
d
p
re
ss
u
re
,
to
ta
l
ch
o
le
st
e
ro
l,
lo
g
e
tr
ig
ly
ce
ri
d
e
s,
b
o
d
y
m
as
s
in
d
e
x,
an
d
d
ia
b
e
te
s
h
is
to
ry
.
Sm
o
ki
n
g
st
at
u
s
re
fe
rs
to
cu
rr
e
n
t,
fo
rm
e
r,
an
d
n
e
ve
r
sm
o
ki
n
g
,
fu
rt
h
e
r
ad
ju
st
m
en
t
fo
r
sm
o
ki
n
g
am
o
u
n
t
(i
.e
.,
ci
g
ar
e
tt
e
s
sm
o
ke
d
p
e
r
d
ay
)
d
id
n
o
t
m
at
er
ia
lly
ch
an
g
e
th
e
o
d
d
s
ra
ti
o
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
m
e
d
.0
0
5
0
0
7
8
.t
0
0
2
Figure 2. Risk of CHD by Fifths of Baseline Circulating IL-6 Levels in a
Pooled Analysis of Participants without Known CHD at Baseline in the
Reykjavik Study and the BRHS
Fifths were calculated on the basis of the distribution of controls in the
combined dataset. CIs were calculated using floating variances. Sizes of
data markers are proportional to the inverse of the variance of the odds
ratios. Adjusted for cohort, age, sex, recruitment period, and town of
recruitment.
doi:10.1371/journal.pmed.0050078.g002
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established cardiovascular risk factors, except potentially by
sex (p ¼ 0.03) and cholesterol levels (p ¼ 0.02), though the
latter were only marginally significant findings in the context
of multiple comparisons (Figure S1).
Correction of Odds Ratios for Within-Person Variability
The regression dilution ratio for loge IL-6 was 0.41 (0.28–
0.53) in 258 individuals who provided paired measurements
on average 4 y apart in the BRHS, similar to the regression
dilution ratio of 0.35 (0.23–0.48) in 300 individuals who
provided paired measurements on average 12 y apart in the
Reykjavik Study (mean loge IL-6 levels at baseline and at
resurvey were 0.76 [SD 0.58] and 0.98 [SD 0.64] pg/ml,
respectively, in BRHS and 0.63 [SD 0.70] and 0.88 [SD 0.68]
pg/ml, respectively, in the Reykjavik Study). Similar point
estimates for the regression dilution ratios of loge IL-6 levels
over 4- and 12-y intervals may reflect that much of the
variability in this marker is related to shorter-term rather
than longer-term factors, although CIs around these esti-
mates were relatively wide. As there were no signification
associations between within-person differences in loge IL-6
levels and time intervals between measurements (p¼ 0.53), it
is unlikely that increasing age of participants explains the
generally higher mean loge IL-6 levels at resurvey. Table 3
indicates that the degree of within-person variability for IL-6
levels over 12 y was generally greater than those for other
measured inflammatory markers and established cardiovas-
cular risk factors (p , 0.05 for each comparison). Figure 3
(with numeric details shown in Table S3) shows three odds
Table 3. Regression Dilution Ratios (95% CI) for IL-6, Other Measured Inflammatory Markers, and Some Established Cardiovascular Risk
Factors, Based on Paired Measurements in Up to 380 Participants in the Reykjavik Study Who Provided Samples Approximately 12
Years Apart
Markers and Risk Factors Variables Number of Participants
Providing Paired Measurements
Regression Dilution
Ratioa (95% CI)
Inflammatory markers Loge IL-6 (loge pg/ml) 300 0.35 (0.23–0.48)
b
Loge C-reactive protein (loge mg/l) 370 0.54 (0.44–0.64)
von Willebrand factor (IU/dl) 378 0.55 (0.45–0.65)
Loge erythrocyte sedimentation rate(loge mm/h) 331 0.64 (0.51–0.76)
Established risk factors Systolic blood pressure (mm Hg) 380 0.65 (0.54–0.76)
Total cholesterol (mmol/l) 379 0.59 (0.51–0.67)
Body mass index (kg/m2) 378 0.90 (0.83–0.97)
Smoking status (current versus never/former) 380 0.59 (0.49–0.68)
aRegression dilution ratio calculated from paired measurements in the Reykjavik Study using Rosner’s regression method, adjusted for baseline age, sex, smoking status, diabetes history,
total cholesterol, loge triglycerides, systolic blood pressure, and body mass index.
bp , 0.05 in comparison of the regression dilution ratio for loge IL-6 versus the regression dilution ratios for each of the other markers in the table.
doi:10.1371/journal.pmed.0050078.t003
Figure 3. Odds Ratios for CHD per 2 SD Increase in Several Inflammatory Markers and Established Cardiovascular Risk Factors Shown with Progressively
Increasing Degrees of Correction for Within-person Variability in a Pooled Analysis of Participants without Known Coronary Disease at Baseline in the
Reykjavik Study and the BRHS
(A) Baseline exposure adjusted for baseline confounders.
(B) Usual exposure adjusted for baseline confounders.
(C) Usual exposure adjusted for usual confounders.
Sizes of data markers are proportional to the inverse of the variance of the odds ratios. Baseline (A) refers to measured values just at the initial
examination. Usual (B and C) refers to an estimate of the long-term average values by employing data on repeat measurements from the Reykjavik
Study (see Methods). Odds ratios are adjusted for cohort, age, sex, period and town of recruitment, smoking status, history of diabetes, total cholesterol,
loge triglycerides, systolic blood pressure, and body mass index.
doi:10.1371/journal.pmed.0050078.g003
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ratios for loge IL-6 and several other risk markers: (i)
assessment 1 lists the odds ratio per 2 SD increase in baseline
levels of the relevant risk marker adjusted for baseline levels
of established risk factors (i.e., uncorrected for within-person
variability in either exposure or confounder levels) (Figure
3A); (ii) assessment 2 lists the odds ratio per 2 SD increase in
usual levels of the relevant risk marker adjusted for baseline
levels of established risk factors (i.e., corrected for within-
person variability only in levels of the exposure) (Figure 3B);
and (iii) assessment 3 lists the odds ratio per 2 SD increase in
usual levels of the relevant risk marker adjusted for usual
levels of established risk factors (i.e., corrected for within-
person variability in levels of both exposure and confound-
ers) (Figure 3C). In assessment 1, the odds ratio for loge IL-6
is similar to those for loge C-reactive protein and systolic
blood pressure, but lower than that for total cholesterol. In
assessment 3, the odds ratio for loge IL-6 is comparable to
those for some established risk factors. Figure 3 shows that
the impact on odds ratios of correction for within-person
variability in confounder levels varied in magnitude among
risk markers, reflecting the markers’ differing strength of
associations with levels of confounders (and the differing
degrees of within-person variability among such confounders
[Table S3]). Sensitivity analyses allowing for uncertainty in
the regression dilution ratios for the exposure variables (but
not in the usual confounder levels, Table S3 legend) gave
slightly wider CIs for the corrected associations.
Updated Meta-analysis
We identified 17 relevant studies [8–21] (including the two
current studies, ten newly identified studies [8–13,17,19–21],
and five studies [14–16,18] included in the previous published
review [22]; flow chart in Figure 1). These studies comprised a
total of 5,730 patients with MI or CHD death and 19,038
control individuals (weighted mean age at entry, 62 y;
weighted mean follow-up, 6 y; Table 4). All studies, with one
exception [20], used enzyme-linked immunosorbent assays
produced by the same manufacturer, and all but two studies
[10,17] adjusted for age, sex, and established cardiovascular
risk factors. Using only within-study comparisons, the
combined odds ratio (95% CI) was 1.61 (1.42–1.83) per 2 SD
increase of baseline IL-6 levels and 3.34 (2.45–4.56) per 2 SD
increase of usual IL-6 levels (Figure 4). Alternatively ex-
pressed, the odds ratios per 1 SD increase in baseline and
usual IL-6 levels were 1.26 (1.19–1.35) and 1.83 (1.56–2.14),
respectively. There was evidence of moderate heterogeneity
among the 17 separate findings (I2¼58%, 95% CI 28%–75%),
but, as displayed in Figure S2, little of it was explained by
differences in sample size (F1,15¼ 0.91, p¼ 0.36), geographical
location (F1,15¼0.30, p¼0.59), population source (F2,14¼0.76,
p¼ 0.49), whether individuals with prevalent CHD at baseline
were excluded from subsequent analyses (F1,15 ¼ 2.08, p ¼
0.17), sex (F2,11¼ 0.16, p¼ 0.85), reported duration of follow-
up (F1,15 ¼ 1.41, p ¼ 0.25), or temperature of blood storage
(F3,13 ¼ 1.19, p ¼ 0.35).
Discussion
Previous reports on IL-6 levels and CHD have not been
able to correct for within-person fluctuations in the levels of
this short-acting cytokine, potentially yielding biased esti-
mates. The present study, which made such correction on the
basis of paired measurements of IL-6, indicates that long-
term average (‘‘usual’’) IL-6 levels are about as strongly
associated with CHD risk as are some major established risk
factors. Increasing IL-6 levels are associated with progres-
sively increasing odds ratios for CHD (i.e., there are
continuous, approximately log-linear relationships). There
are moderate associations of IL-6 levels with some established
risk factors (notably smoking, diabetes, and dyslipidemia) and
with several downstream inflammatory markers, consistent
with the key role of IL-6 in mediating inflammatory cascades
[3–5,41–44]. The current findings do not, of course, establish
causality, but they may have implications for understanding
disease mechanisms and for further research strategies.
By showing that pathways mediated by long-term IL-6
levels are associated with CHD risk about as strongly as are
some major established risk factors, the current data
reinforce interest in the connection between inflammatory
pathways and cardiovascular diseases. The data also under-
score the need for investigations of proximal inflammatory
mediators that can quantify and correct for within-person
variability. Serious underestimation is likely without such
correction because, as demonstrated in the current study, the
variability in IL-6 levels is substantially higher than for
downstream inflammatory markers and several established
CHD risk factors. Hence, given the central role of IL-6 levels
in inflammatory pathways and its continuous association with
CHD risk, it warrants further investigation as a plausible
potential therapeutic target. There are initial reports of
reductions in circulating IL-6 concentrations in randomised
trials of statins, although these agents have other effects,
notably lowering low-density lipoprotein cholesterol [45–47].
Future investigations should involve complementary strat-
egies to help judge causality, such as large-scale studies of
specific genetic markers as proxies for circulating IL-6 levels
[48] (although it is now uncertain whether the174 G/C IL-6
polymorphism is materially correlated with IL-6 levels [49])
and, possibly, use of selective IL-6 antagonists in early
randomized trials [50], although the pleiotropic actions of
IL-6 could complicate such an approach.
The strengths and potential limitations of the present
report merit careful consideration. The current study reports
new data from two population-based prospective cohorts
comprising more than four times as many patients with first-
ever CHD than in the previous largest report. Both the
Reykjavik Study and BRHS identified participants in pop-
ulation registers, involved high response and follow-up rates,
and involved robust ascertainment of incident MI and
coronary death. Their broadly similar results support the
generalisability of the current findings. Assay methods used in
the current study were similar to those in earlier reports,
yielding similar median IL-6 levels (Table 4). Although the
current studies involved more prolonged blood storage than
previous studies, they produced associations with CHD risk at
least as strong as in earlier studies, arguing against under-
estimation due to sample degradation. Paired IL-6 (and
other) measurements enabled approximate correction for
within-person variability in a way that implies that long-term
average IL-6 values are relevant to CHD risk, consistent with
prevailing hypotheses of sustained low-grade inflammation,
but it is not clear why mean loge IL-6 levels were generally
higher at resurvey examinations.
In comparison with a previous nonquantitative review [22],
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the current meta-analysis involved almost five times as many
incident CHD cases from population-based prospective
studies (thereby enhancing statistical power), strictly defined
CHD as MI or fatal CHD (thereby enhancing accuracy of
disease classification), excluded (where possible) people with
prevalent cardiovascular disease (thereby limiting potential
biases), and explored in detail potential sources of hetero-
geneity (thereby probing possible causes of study diversity).
This updated review suggests that the apparently divergent
estimates reported in earlier studies were probably chiefly
due to random error. Further studies are needed to test
whether associations of IL-6 with CHD are importantly
modified by lipid concentrations, as suggested by exploratory
analyses in the current report. Studies are also needed with
serial measurements in larger numbers of participants over
different intervals in order to assess IL-6 variability in greater
detail (e.g., assessment of any changes in mean levels and
variability over time). This information will enable study-
specific and time-dependent correction for regression dilu-
tion [23,51,52], whereas in the current meta-analysis the
correction factor was derived from repeat measurements in
only the Reykjavik Study. Adjustment for within-person
variability in both exposure and confounder levels across all
available studies will require access to individual participant
data, as demonstrated by such adjustment in the current
analyses of the Reykjavik Study and BRHS.
Conclusion
Long-term IL-6 levels are associated with CHD risk about
as strongly as are some major established risk factors, but
causality remains uncertain. These findings highlight the
potential relevance of IL-6–mediated pathways to CHD.
Supporting Information
Figure S1. Association of Baseline Circulating Loge IL-6 Levels and
CHD Risk in a Pooled Analysis of Participants without Known CHD
at Baseline in The Reykjavik Study and the BRHS, Grouped by Several
Participant Level Characteristics
Found at doi:10.1371/journal.pmed.0050078.sg001 (60 KB PPT).
Figure S2. Seventeen Prospective Studies of Baseline IL-6 levels and
Risk of CHD, Grouped According to Several Study Characteristics
Found at doi:10.1371/journal.pmed.0050078.sg002 (8 KB PPT).
Table S1. Data Abstraction Form for Systematic Review of IL-6 and
CHD
Found at doi:10.1371/journal.pmed.0050078.st001 (49 KB DOC).
Table S2. Comparison of Levels of Risk Factors and Other
Characteristics by Thirds of Baseline IL-6 Levels among Non-CHD
cases in a Pooled Analysis of the Reykjavik Study and the BRHS
Found at doi:10.1371/journal.pmed.0050078.st002 (103 KB DOC).
Figure 4. Summary of 17 Prospective Studies Reporting Adjusted Associations of CHD Risk per 2 SD Increase in Baseline IL-6 Levels and Usual IL-6
Levels, with Both Adjusted Only for Baseline Levels of Several Established Risk Factors
(A) Baseline exposure adjusted for baseline confounders.
(B) Usual exposure adjusted for baseline confounders.
Baseline refers to measured values just at the initial examination. Usual refers to an estimate of the long-term average values. The correction for
regression dilution (see Methods) in the two current studies (filled squares) was done using study-specific regression dilution ratios of 0.35 in Reykjavik
study and 0.41 in the BRHS. A regression dilution ratio of 0.4 was assumed for other studies (empty squares) where such regression dilution ratio
coefficients were unavailable. The odds ratio for a 1 SD increase in baseline and usual IL-6 levels are 1.26 (1.19–1.35) and 1.83 (1.56–2.14), respectively.
Unshaded data markers were used in the second plot of this figure to indicate that correction for regression dilution involved use of coefficients from
external studies, in contrast with the cohort-specific data on IL-6 variability available for the Reykjavik Study and BRHS. Sizes of data markers indicate the
weight of each study in the analysis. Adjustment for within-person variability in levels of IL-6 and possible confounders requires access to individual
participant data, currently available only in the Reykjavik Study and BRHS.
þ, adjusted for age and sex;þþ, adjusted for age, sex, and smoking status;þþþ, adjusted for age, sex, smoking status, and other established CHD risk
factors; FINRISK, Finnish National Risk Factor Survey; HPFUS, Health Professionals’ Follow-up Study; MONICA, MONItoring of trends and determinants in
Cardiovascular disease; PRIME, Prospective Epidemiological Study of Myocardial Infarction; WHIOS, Women’s Health Initiative Observational Study;
WOSCOPS, West of Scotland Coronary Prevention Study.
doi:10.1371/journal.pmed.0050078.g004
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Table S3. Comparisons of Odds Ratios for CHD with Baseline and
Usual (i.e., Corrected for Within-person Variability) Levels of Four
Circulating Inflammatory Markers and Two Established Cardiovas-
cular Risk Factors in a Pooled Analysis of Data for Participants
without Known Coronary Disease at Baseline in the Reykjavik Study
and the BRHS
Found at doi:10.1371/journal.pmed.0050078.st003 (41 KB DOC).
Text S1. Protocol for Systematic Review of Prospective Studies of IL-
6 and Coronary Disease
Found at doi:10.1371/journal.pmed.0050078.sd001 (33 KB PDF).
Text S2. The QUOROM Statement Checklist
Found at doi:10.1371/journal.pmed.0050078.sd002 (48 KB DOC).
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Editors’ Summary
Background. Coronary heart disease (CHD), the leading cause of death
among adults in developed countries, kills one person in the US every
minute. With age, ‘‘atherosclerotic plaques’’—deposits of fats, calcium,
and various cellular waste products—coat the walls of arteries, causing
them to narrow and harden, interrupting blood flow through the body.
When this occurs in the coronary arteries, which nourish the heart
muscle, the end result is CHD. If a plaque breaks off the artery wall, it can
get trapped in the arteries and completely stop the blood flow, causing
death of the heart muscle. The technical term for this is ‘‘myocardial
infarction’’ (MI), although it is more commonly known as a heart attack.
Smoking, high blood pressure, high blood levels of cholesterol (a type of
fat), being overweight, and being physically inactive all increase the risk
of developing CHD, as do some inherited factors. Treatments for CHD
include lifestyle changes (for example, losing weight and exercising
regularly) and medications that lower blood pressure and blood
cholesterol. In the worst cases, the narrowed artery can be widened
using a device called a stent or surgically bypassed.
Why Was This Study Done? Atherosclerosis might, at least partly, be an
inflammatory condition. Inflammation—an immune response to injury
characterized by swelling and redness—involves the production of
proteins called ‘‘cytokines,’’ which attract cells of the immune system to
the site of injury. In atherosclerosis, damage to the artery walls seems to
trigger inflammation, which helps the atherosclerotic plaques grow.
Because of the potential involvement of inflammation in atherosclerosis,
increased levels of circulating cytokines might be associated with an
increased risk of CHD. If they are, cytokines might provide a new
therapeutic target for the treatment of CHD. In this study, the researchers
have asked whether prolonged moderate increases in the cytokine
interleukin-6 (IL-6) in the bloodstream are associated with CHD risk. IL-6,
which is produced very early in inflammation, survives only briefly in the
human body and its levels fluctuate within individuals. Consequently, its
relevance to CHD has been unclear in previous studies.
What Did the Researchers Do and Find? Between 1967 and 1991,
nearly 25,000 healthy, mainly middle-aged people were enrolled into
two studies—the Reykjavik Study and the British Regional Heart Study—
and followed for about 20 years, during which time 2,138 people had a
first-ever nonfatal heart attack or died of CHD. The researchers measured
baseline IL-6 blood levels in these participants and in 4,267 similar
participants who had not had a CHD event. They also measured IL-6
levels in 558 healthy participants several years into the study to
determine a ‘‘regression dilution ratio’’ for IL-6. This ratio gives an idea of
the year-to-year consistency of IL-6 levels. When the researchers used
this ratio to estimate the impact of prolonged increases in IL-6 levels on
CHD, they found that increased long-term IL-6 levels more than doubled
the risk for CHD in their study populations. The researchers then
combined these new results with those of 15 previous relevant studies.
This combined analysis indicated very similar findings to those in the
new data.
What Do These Findings Mean? These findings indicate prolonged
moderate increases in IL-6 levels are associated with risk of CHD as
strongly as several major established risk factors, including blood
pressure and blood cholesterol levels, but whether there is a cause-
and-effect relationship remains unknown. More studies are needed to
find out whether this result is generalisable to other populations, but the
broad agreement between the Icelandic and British studies suggests that
they should be. This study renews interest in IL-6–mediated inflamma-
tory pathways and CHD.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050078.
 Read a related PLoS Medicine Perspective article
 The MedlinePlus encyclopedia has pages on coronary heart disease
and atherosclerosis (in English and Spanish)
 Information is available from the US National Heart Lung and Blood
Institute on coronary heart disease and atherosclerosis
 Information for patients and caregivers is provided by the American
Heart Association on all aspects of heart disease, including
inflammation and heart disease
 Information is available from the British Heart Foundation on heart
disease and on keeping the heart healthy
 Further details are available about the Reykjavik Study and the British
Regional Heart Study
 Wikipedia has pages on inflammation and on interleukin-6 (note that
Wikipedia is a free online encyclopedia that anyone can edit; available
in several languages)
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